AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02935673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration of matching placebo.
Study NCT02453269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdisciplinary program
Study NCT03546751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet And Exercise
Description: This will consist of weekly telephone and monthly face to face visits to monitor and suggest measures to improve diet and regular exercise as conducted by a registered dietician.
Study NCT04048642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH
Description: 7 days of a DASH diet
Study NCT04048642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole-Food, Plant-Based
Description: 7 days of a WFPB diet
Study NCT02653651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine infused at 0.1 mg/kg/hour
Study NCT02653651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine infused at 1 mg/kg/hour
Study NCT02653651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of saline
Study NCT00788827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ stem cells
Description: Up to 5 x 10 log 8 of autologous stem cells on a single occasion
Study NCT02685631 — intervention group
Intervention type: OTHER
Intervention: Yttrium-90 Resin Microspheres
Description: Data collection into the RESIN registry
Study NCT02800356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subthreshold 577 nm yellow wavelength laser photo-coagulator
Description: Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management.
Study NCT01297907 — intervention group
Intervention type: OTHER
Intervention: Methacholine Challenge Test
Description: Methacholine challenge test to evaluate airway hyperreactivity
Study NCT03681067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
Study NCT03681067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- sodium chloride
Description: Placebo injectable solution will be delivered via intravenous infusion as a single infusion
Study NCT01297907 — intervention group
Intervention type: OTHER
Intervention: Fractional Exhaled NO (FENO)
Description: Fractional Exhaled NO to evaluate eosinophilic inflammation
Study NCT01297907 — intervention group
Intervention type: OTHER
Intervention: Blood Test
Description: Blood Tests (Eosinophil Count)
Study NCT01297907 — intervention group
Intervention type: OTHER
Intervention: PCDAI
Description: Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
Study NCT01120756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-oriented attentional self-regulation
Description: This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
Study NCT01120756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Education
Description: Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
Study NCT02265055 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfer early cleavage embryos
Description: transfer early cleavage embryos
Study NCT02265055 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfer non early cleavage embryo
Study NCT00446147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 100mg BID/daily, Per oral
Study NCT00446147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 100mg BID/daily, Per oral
Study NCT02660320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
Study NCT02660320 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser placebo
Description: The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
Study NCT00266305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fish oil (Dry n-3, BASF)
Description: 5 g/oil daily for the first four month of lactation
Study NCT05211128 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic Surgery
Description: Surgical procedure using robotic technologies.
Study NCT05211128 — intervention group
Intervention type: PROCEDURE
Intervention: Open Surgery
Description: Surgical procedure using a large, open cut in the skin.
Study NCT05211128 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Surgical procedure using small incisions and trochars.
Study NCT01200797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJG-136
Description: Given IV
Study NCT00266305 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil (Dry n-3, BASF)
Description: 5 g/oil daily for the first four month of lactation
Study NCT01248715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: These patients will receive early (within 8-12 hours of admission, no later than 24 hours after admission) oseltamivir plus current, standard empiric antibacterial therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP (2). Anti-influenza therapy will be given using oseltamivir at a dose of 75 mg twice daily. The oseltamivir dose will be adjusted in patients with renal insufficiency according to the package insert. Duration of antiviral therapy will be for a minimum of 5 days for patients with evidence of early clinical improvement and prolonged depending on clinical stability
Study NCT03665714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Impact Oral
Description: Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
Study NCT03665714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Impact Oral
Description: Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
Study NCT03665714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Nutrition Emulsion(TPF-T)
Description: TPF-T
Study NCT03665714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition Emulsion(TPF-T)
Description: TPF-T
Study NCT01200797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01644175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
Study NCT02377648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)
Description: Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS \<70%) associated with concomitant signs or symptoms of myocardial ischemia.
Study NCT02632487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Center-based walking + balance, stretching, and light resistance
Study NCT02632487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Center-based walking + balance, stretching, and light resistance
Study NCT03270839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kwells
Description: Motion sickness drug
Study NCT03270839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: No active substance in the tablet
Study NCT02632487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Exercise Physical Activity (NEPA)
Description: Behavioral counseling paired with technology intervention to monitor physical activity
Study NCT03748719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT treatment
Study NCT01839149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI-001
Description: TI-001 is intranasal oxytocin
Study NCT00674739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: daily topical application for up to 8 weeks
Study NCT00674739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.75% imiquimod cream
Description: 3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
Study NCT00674739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: placebo cream applied daily to wart areas for up to 8 weeks
Study NCT00154154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Psychiatric Management
Description: General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.
Study NCT00154154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy
Description: Modification of behaviours achieved with reframing thoughts and impulses
Study NCT03980652 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Change of gloves and sterile instruments
Description: Change of gloves and use of separate , sterile instruments before closing the abdominal wall
Study NCT03108131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03108131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study NCT03106324 — intervention group
Intervention type: DRUG
Intervention: Revlimid (lenalidomide)
Description: Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
Study NCT00657189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: 100 mg once; SC Placebo × 12 doses on other weeks
Study NCT00657189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: 100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
Study NCT00657189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: 100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
Study NCT00657189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: 100 mg every week × 13 doses
Study NCT00657189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC Placebo every week × 13 doses
Study NCT01482312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
Study NCT01482312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
Study NCT01482312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glasses
Description: Glasses per habitual prescription
Study NCT03106675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T
Description: Procedure is performed under proper analgesia (general or local anesthesia). The intervention can be performed in areas accessible with ultrasound with no critical structures (nerves, vasculature, bowels) in proximity. Limbs and pelvis are most usually accepted locations.~Patient is adjusted on top of the HIFU-transducer connected to MRI. First a MR-scan is performed and the treatment procedure is planned on consol. Then under MRI-guidance a point by point ablation of the target tumor is performed. During the treatment a real-time thermometry is obtained in order to avoid unwanted heating of related structures and to observe sufficient effect on treatment zone. After treatment MR-scan with gadolinium is performed to evaluate the size of ablated area.
Study NCT03106675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Varian Truebeam Radiotherapy System
Description: Conventional radiotherapy focused on bone tumor. Pretreatment planning images acquired with computer tomography
Study NCT02665156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal stapled neobladder using robotic staplers
Description: Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana.
Study NCT00811967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
Study NCT00811967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
Study NCT02235454 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SDOCT-GMPE software
Description: Noninvasive imaging of the optic nerve in patients with existing glaucoma
Study NCT04016519 — intervention group
Intervention type: OTHER
Intervention: Gastrostomie
Description: Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term.
Study NCT01839149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01252030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: physical activity monitors
Description: physical activity monitors
Study NCT01252030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No physical activity monitors
Description: No physical activity monitors
Study NCT02682082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided celiax plexus neurolysis
Description: Endoscopic ultrasound-guided celiax plexus neurolysis
Study NCT02682082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided celiax plexus neurolysis
Description: Endoscopic ultrasound-guided celiax plexus neurolysis
Study NCT02682082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
Study NCT01586221 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Music & Physical Therapy
Description: Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
Study NCT03406117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAT1
Description: All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.
Study NCT03406117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: Only for CIT portion of the study. Participant will have product applied topically on site by the trained study staff.
Study NCT01870726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily.
Study NCT01870726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
Study NCT01452581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: Maximal 2 units of packed red blood cells given one at a time on the first postoperative day. Evaluation of primary outcome is done after administration of each unit.
Study NCT01452581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Voluven
Description: Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
Study NCT01644175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
Study NCT01644175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study NCT01644175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study NCT01822132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release naltrexone
Study NCT01822132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04328831 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IBI322
Description: Recombinant anti-human CD47/PD-L1 bispecific antibody injection
Study NCT04100707 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Genicular block was applied
Description: This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
Study NCT04100707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genicular block was applied
Description: This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
Study NCT04684147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of CNCT19
Description: Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
Study NCT01542385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
Study NCT01542385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
Study NCT04249258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Dobutamine will then be administered at doses of 5mcg/kg/min, 10mcg/kg/min, 15mcg/kg/min and 20mcg/kg/min.